AI주식인사이트AI Stock Insight
C

풍전약품

298060KOSDAQ의약품 제조업

53.0 / 100

Reference Date: 2026-06-10

Financial Score17.5 / 40
News Sentiment12.5 / 25
Momentum13.0 / 20
Disclosure10.0 / 15
AI Analysis: PBR is significantly undervalued vs. peers but PER raises overvaluation concerns. Surged 192.3% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

SCM Life Science is a biotech company that develops high-purity stem cell therapeutics using its proprietary layer separation culture technology. It is conducting clinical trials for treatments targeting chronic graft-versus-host disease, acute pancreatitis, and atopic dermatitis. Additionally, it has launched the dermocosmetic brand 'Iroro,' leveraging CXCL1 protein and hPL cultivation technology, and is expanding globally through international sales agreements.

Number of Employees

25people

Average Salary

37.2M KRW

Score Calculation Basis

Detailed Financial Score

PER
451.67Industry Average 11.930.0Point

37.9x industry avg (risky)

PBR
0.66Industry Average 0.895.5Point

Lower than industry avg (good)

ROE
0.81Industry Average 4.011.0Point

Well below industry avg

Debt Ratio
7.36Industry Average 12.435.0Point

Lower than industry avg (good)

Trend 2023~20256.0 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲1404.4% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲36.5% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -59.1% (improving, 3yr)

Detailed News Sentiment

1 totalPositive 0Neutral 1Negative 0Average Sentiment Score 50

Detailed Momentum

52-week position6.0Point

52w upper range (66%)

Current 2,710Won52-week high 3,70552-week low 764
1-month return6.0Point

1m +192.34% (strong rise)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-09
  • Neutral[기재정정]주주명부폐쇄기간또는기준일설정2026-06-04
  • Neutral[기재정정]주주총회소집결의2026-06-04
  • Neutral주권매매거래정지해제 (액면병합 주권 변경상장)2026-05-18
  • Neutral분기보고서 (2026.03)2026-05-14